Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
相关临床试验
12
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
8
66.7%
招募中
1
8.3%
终止
3
25.0%
暂无批准数据
- Aprea Therapeutics announced an expanded intellectual property portfolio now comprising 28 issued patents and 30 pending applications across the U.S. and international markets. - The WEE1 kinase inhibitor program, led by APR-1051, is protected by pending applications that could extend exclusivity through 2047, excluding potential regulatory exclusivities. - The ATR inhibitor program, anchored by ATRN-119, holds granted patents expiring 2035–2037, with pending applications potentially extending protection into 2045. - Aprea is advancing APR-1051 in the ACESOT-1051 Phase 1 trial and considering combination approaches for ATRN-119 with radiation, chemotherapy, ADCs, and immune checkpoint inhibitors.
- DNA Damage Response inhibitors surpassed $7 billion in global sales in 2025, with the broader oncology market projected to approach $500 billion by 2032. - Onco-Innovations is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor that extended median survival to 60 days versus 23 days in PTEN-deficient colorectal cancer mouse models. - The company holds exclusive global rights across three IP layers—core molecules, nanoparticle delivery, and synthetic lethality applications—with a first-in-human phase 1 trial anticipated for late 2026. - Artios Pharma, MD Anderson, and Repare Therapeutics have all generated clinical signals from novel DDR targets beyond PARP, confirming the sector's investable maturity.
- Aprea Therapeutics has appointed industry veteran Eugene Kennedy, MD, as Chief Medical Advisor following early clinical proof-of-concept demonstrated in its ongoing Phase 1 study of WEE1 inhibitor APR-1051. - Dr. Kennedy brings over 20 years of oncology clinical development experience and has previously served as Chief Medical Officer at multiple biotechnology companies including Carisma Therapeutics and Galera Therapeutics. - The appointment strengthens Aprea's clinical leadership as the company advances dose escalation and refines patient selection for its DNA damage response program targeting multiple solid tumor types.
- Aprea Therapeutics' WEE1 inhibitor APR-1051 achieved two unconfirmed partial responses in endometrial cancer patients with PPP2R1A mutations at 150 mg and 220 mg dose levels. - The Phase 1 ACESOT-1051 trial has enrolled 22 patients across multiple solid tumor types, with five additional patients achieving stable disease. - APR-1051 demonstrated favorable tolerability and potential dose-response trends across genomically defined cancers, supporting continued clinical development.
- Aprea Therapeutics raised $3.1 million through a private placement priced at-the-market under Nasdaq rules, with participation from new and existing healthcare-focused investors. - The financing is expected to extend the company's cash runway into Q1 2027, providing funding for continued development of its cancer vulnerability-targeting approach. - Aprea's lead programs include APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development for solid tumor indications. - The company's innovative approach aims to exploit cancer cell mutations while minimizing damage to healthy cells, potentially reducing toxicity compared to traditional chemotherapy.
- Aprea Therapeutics' WEE1 inhibitor APR-1051 demonstrated disease stabilization in 3 out of 4 patients at 100 mg once daily in heavily pretreated gastrointestinal and gynecologic cancers. - The company identified a recommended Phase 2 dose of 1,100 mg once daily for ATRN-119, its first-in-class macrocyclic ATR inhibitor targeting DNA damage response pathways. - Both clinical programs are advancing with manageable safety profiles, focusing on biomarker-defined patient populations with high unmet medical needs. - Aprea is strategically pausing enrollment to explore combination strategies with radiation therapy and checkpoint inhibitors to maximize therapeutic benefits.
• Dr. Eyal Attar joins Halda Therapeutics as Chief Medical Officer, bringing over 25 years of biotechnology R&D and clinical trial experience to advance the company's novel RIPTAC cancer therapy platform. • Halda is currently conducting a Phase 1/2 clinical trial of HLD-0915, their lead candidate targeting metastatic castration-resistant prostate cancer (mCRPC) through a unique "hold and kill" mechanism designed to overcome resistance. • The RIPTAC platform represents a new therapeutic modality that creates neomorphic protein-protein interactions to selectively target cancer cells, with programs in development for prostate cancer, breast cancer, and other serious diseases.
- Aprea Therapeutics has dosed the first HPV+ head and neck squamous cell carcinoma (HNSCC) patient in Cohort 5 of the ACESOT-1051 trial, evaluating their WEE1 kinase inhibitor APR-1051. - The company recently established a Material Transfer Agreement with MD Anderson Cancer Center to explore APR-1051's potential in treating HPV+ and HPV- HNSCC with genomic markers of replication stress. - Open label data from the ACESOT-1051 clinical trial is expected in the second half of 2025, with researchers noting encouraging safety profiles to date.
• Aprea Therapeutics initiates twice-daily dosing of ATRN-119 at 550mg in the ABOYA-119 Phase 1/2a trial to maintain optimal therapeutic levels. • The trial evaluates ATRN-119 as a monotherapy for advanced solid tumors with DNA damage response gene mutations, potentially enhancing efficacy. • Phase 1 readout is anticipated in the second half of 2025, with dose escalation continuing independently for both once-daily and twice-daily schedules. • ATRN-119 is the first macrocyclic ATR inhibitor in clinical trials and the only one tested as a monotherapy on a continuous twice-daily schedule.
- Aprea Therapeutics is progressing its Phase 1 ACESOT-1051 trial of APR-1051, a WEE1 inhibitor, showing promising tolerability in treating cancers with Cyclin E over-expression. - The company's Phase 1/2a ABOYA-119 study is evaluating ATRN-119, an ATR inhibitor, for patients with DDR-related gene mutations, addressing a significant unmet medical need. - Aprea Therapeutics reported $26.2 million in cash reserves, ensuring funding for at least the next twelve months, and appointed Dr. Philippe Pultar as a senior medical advisor.
